Form 4: BioCryst Pharmaceuticals CFO Sells Shares to Cover Tax Obligations

BioCryst Pharmaceuticals' Chief Financial Officer, Anthony Doyle, sold 7,890 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, sold 7,890 shares of common stock on December 14, 2024.
• The sale was executed at a price of $7.53 per share.
• This transaction was not a discretionary sale but rather a withholding of shares by the company to cover tax obligations related to the vesting of restricted stock units.
• Following the transaction, Mr. Doyle directly owns 259,628 shares of BioCryst Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It does not indicate any change in the company's outlook or performance.

Comparison to Industry Standards

• Tax-related stock sales by executives are a common practice across the pharmaceutical industry and other sectors.
• Many companies use restricted stock units as part of executive compensation packages, which often trigger tax liabilities upon vesting.
• The number of shares sold is relatively small compared to the total shares owned by the CFO, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale for tax purposes and does not indicate a change in the company's fundamentals.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Anthony Doyle, CFO, stock sale, tax withholding, restricted stock units, insider trading